Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DD - Updated Collection Of Recent Articles And Videos With The Most Recent First:
Go to Anavex.com for press releases and more info on the Company
http://www.marketwatch.com/story/anavex-receives-notice-of-allowance-for-us-patent-application-related-to-anavex-2-73-2015-08-12
NEW YORK, Aug 12, 2015 (GLOBE NEWSWIRE via COMTEX) --
Anavex Life Sciences Corp. ("Anavex" or the "Company") (otcqx:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Pat. App. No. 14/205,637 related to ANAVEX 2-73. Upon issuance, the patent will provide intellectual property (IP) protection until at least 2035. ANAVEX2-73 is the subject of an ongoing Phase 2a clinical trial for the treatment of Alzheimer's disease.
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1450
Impact on Diagnosis/Treatment of Parkinson’s:
The present study holds potential to impact the way Parkinson’s disease is treated. We aim to develop a new pharmacological approach to boost repair mechanisms and dampen inflammation in the part of the brain that is most affected by Parkinson’s. If this treatment exerts the expected effects, it could slow the progression of the disease.
Next Steps for Development:
If successful, this study will accelerate the translation of pre-clinical findings into the first clinical trial of ANAVEX2-73 as a potential disease-modifying therapy for Parkinson’s disease. ANAVEX2-73 has already been tested for safety and tolerability in humans with positive results.
http://seekingalpha.com/article/3354415-interview-with-dr-christopher-missling-ceo-of-anavex?auth_param=d2ta:1ar4d6c:74ced639ac1ecb22d9cbea5192bcfa90
KKD - So, until you get the patent assigned to you, you cannot begin the Anavex Plus trial, correct?
CM - No. All patents are irrevocably assigned or owned by Anavex.
http://seekingalpha.com/article/3354385-anavex-may-actually-cure-alzheimers
Anavex May Actually Cure Alzheimer's
https://au.news.yahoo.com/video/watch/29015798/new-pills-offer-hope-for-alzheimers-sufferers/#page1
"It's like being in the dark and someone switched the light on."
http://www.heraldsun.com.au/news/victorians-first-to-trial-breakthrough-brain-booster-pill/story-fni0fiyv-1227453139615
A PILL to treat Alzheimer’s disease is four times more effective than the current treatment in boosting the brain power of patients.
“We’ve also had patients and their carers reporting improvements in their thinking, increased alertness and improvement in their organisation and independence,” Prof Macfarlane said.
http://thestockradio.com/otcqx-avxl-anavex-life-sciences-corp-ceo-pres-christopher-missling-2050.html
http://www.anavex.com/
Corporate Presentation - Spring 2015
http://www.endevr.com/dementia/New-drug-might-help-prevent-slow-or-reverse-Alzheimer-s
Findings in a recent peer-reviewed scientific journal reveals that our lead drug, ANAVEX 2-73 has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.
readytogo123, the 10-Q info I posted was derived from this PR dated 3-27-14. This PR was released before the human trials began. The info in this PR is predictive and has nothing to do with actual trial results.
Anavex Reports Predicted Clinical Effect of Both Anavex 2-73 and Anavex Plus in a Humanized Cortical Cognitive Model for Alzheimer's Disease
New York, NY — March 27, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer, today announced that a report in the current issue of peer-reviewed International Pharmaceutical Industry Journal (“IPI Journal”) predicts that ANAVEX 2-73 will have a meaningful effect in Alzheimer’s disease based on the Alzheimer’s Disease Assessment Scale-Cognitive (“ADAS-Cog”), especially when combined with donepezil (Aricept®), the world’s best-selling Alzheimer’s drug. The Company believes this drug combination, called ANAVEX PLUS, is a compelling commercial opportunity because of its potential to treat symptoms of Alzheimer’s while also possibly modifying or reversing the course of the disease. A Phase 1b/2a clinical trial of ANAVEX PLUS, is scheduled to begin mid 2014.
The findings, utilizing a predictive humanized calibrated cortical cognitive model for Alzheimer’s Disease in, which was focusing on symptomatic effects based on the M2 antagonistic target engagement level of ANAVEX 2-73, predict that ANAVEX PLUS, combining ANAVEX 2-73 with low dose (5mg) donepezil (Aricept®), will show a significantly improved clinical outcome versus when the drugs are administered individually. ANAVEX PLUS is expected to show up to 9 points improvement in ADAS-Cog at 12 weeks and 6 points at 26 weeks in mild-to-moderate Alzheimer’s patients, respectively, at target engagement levels of approximately 70%. When administered alone, ANAVEX 2-73 is expected to improve ADAS-Cog by 5 points at 12 weeks, and 3 point at 26 weeks, which is also likely to be detected clinically. As a point of reference, in human clinical trials 5 mg donepezil (Aricept®) was reported to show an average improvement of 3.6 points ADAS-Cog at 12 weeks and 2.6 at 26 weeks, respectively.
“This data, as reported in IPI Journal, confirms the strong synergy we have previously seen preclinically between ANAVEX 2-73 and donepezil. It also supports the advancement of ANAVEX PLUS into a Phase 1b/2a trial,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “The same type of computer model is in use by big pharmaceutical companies to predict the difference between rodent and human brains as well as the anticipated clinical trial outcome. Therefore, the computer simulation model is believed to have reduced the trial risk for ANAVEX PLUS.”
The report, entitled “The Anticipated Clinical Effect of the new Alzheimer Drug ANAVEX PLUS in a Predictive Humanized Cortical Cognitive Model for Alzheimer’s Disease,” was co-authored by Drs. Missling, Maurice and Geerts, Chief Scientific Officer of In Silico BioSciences (ISB) and Adjunct Professor at the School of Medicine at the University of Pennsylvania, along with industry colleagues.
http://www.anavex.com/?post_type=news&p=990
The following is from the 10-Q and is one of the reasons I held AVXL through the 7/22data release -
In a humanized calibrated cortical network computer model the unexpected pre-clinical synergy between ANAVEX 2-73 and donepezil was confirmed and ANAVEX PLUS showed an anticipated ADAS-Cog response of 7 points at 12 weeks and 5.5 points at 26 weeks, which represents more than 2x the ADAS-Cog of donepezil alone.
Welcome BooDog,
I bought in late April and have held since. Added at .79 and 1.01. I was a bit nervous holding through the first Phase 2 data release. I feel a lot more comfortable now holding through future data releases.
fourdueces, the daily short volume is meaningless. Ignore those numbers.
When a MM accepts a sell order from a broker (posts it, and it fills), without having the shares in his inventory, he is temporarily short the stock he has to deliver to the buyer. This short is reported as short volume (not to be confused with short sales) even though he will usually have the shares in hand (from broker) in a nano-second from the seller (broker). Only the first part of the transaction is reported to Finra. It is reported as short volume. The almost instant cover is not reported to eliminate double counting of the sell order.
This is why the daily short volume some people like to focus on is meaningless. Only the bi-monthly short sales reported by the exchanges are meaningful.
On July 31, 2015 the total short interest for AVXL was 5,778,515 shares. Days to cover 1, which means the short interest is equal to 1 day of average volume. Notice in the link below that AVXL is OTCQX, NOT PINK!
http://www.otcmarkets.com/stock/AVXL/short-sales
You can easily see that the daily short volume is covered right away and not carried over -
That info you posted is from May,2014. A lot has changed since then.
Do you have another alias (Tom)?
Seriously, read the sticks!!!
I can't say that I would like to see them give more data at a conference in Sept?
I'm hoping AVXL will release another tranche of top line results at the September 9th conference.
They haven't announced that they'll be there. Just wishful thinking on my part.
LOL, great Yahoo post by stephata -
After there approval for Alzheime/Parkinson/ Eplilepsy/Cancer/ and best off all it cures Stupid
Hi mapman1010, I wouldn't be surprised if the trial is fully enrolled by now either.
Up until the time AVXL decided to release partial top line results in July, they expected to release top line results in September. They didn't say partial top line results in September, just said top line results.
I think they will have the rest of the trials top line results by the end of September. I'm hoping AVXL will release another tranche of top line results at the September 9th conference.
This is what CEO Missling had to say about the Phase 2A trial -
“Speaking of the ongoing trial, the company wanted to avoid the same failure that the other Alzheimer’s drug trials experienced,” Missling told BioSpace. “Therefore, we designed our trial to be a more efficient study than a conventional study with the implementation of an adaptive trial design. We are proud to utilize the latest FDA guidelines in our trial in order to gather as much information as we can from each patient. The data we will gather from this trial will lay a great foundation to lead to a more successful Phase III trial.”
http://www.biospace.com/News/tricon-alzheimers-drug-saw-80-reversal-in-memory/365180
Notice how Dr. Missling was already talking about "a more successful Phase III trial".
http://www.endevr.com/dementia/New-drug-might-help-prevent-slow-or-reverse-Alzheimer-s
Findings in a recent peer-reviewed scientific journal reveals that our lead drug, ANAVEX 2-73 has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.
I like the Lincoln Park financing -
Where did you see the latest short numbers?
OTC Markets still shows Jul 15, 2015 3,617,571
Thanks
wildcard235, below is something I posted a couple days ago in regard to daily short numbers -
When a MM fills a sell order, without having the shares in his inventory, he is temporarily short the stock. This short is reported as short volume (not to be confused with short sales) even though he will have the shares in hand in nano-seconds from the seller. Only the first part of the transaction is reported to Finra as short volume. The almost instant cover is not reported to eliminate double counting of the sell order.
This is why the daily short volume some people like to focus on is meaningless. Only the bi-monthly short sales reported by the exchanges are meaningful.
Dok, the chart was using 30 minute time periods. Clay called out the support as the 200 (30 minute) period sma. I believe the resistance moving average is the 50 (30 minute) period sma.
Don't get greedy.
Added at $1.01 - Cheap!!!
DD - Updated Collection Of Recent Articles And Videos With The Most Recent First:
Go to Anavex.com for press releases and more info on the Company
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1450
Impact on Diagnosis/Treatment of Parkinson’s:
The present study holds potential to impact the way Parkinson’s disease is treated. We aim to develop a new pharmacological approach to boost repair mechanisms and dampen inflammation in the part of the brain that is most affected by Parkinson’s. If this treatment exerts the expected effects, it could slow the progression of the disease.
Next Steps for Development:
If successful, this study will accelerate the translation of pre-clinical findings into the first clinical trial of ANAVEX2-73 as a potential disease-modifying therapy for Parkinson’s disease. ANAVEX2-73 has already been tested for safety and tolerability in humans with positive results.
http://seekingalpha.com/article/3354415-interview-with-dr-christopher-missling-ceo-of-anavex?auth_param=d2ta:1ar4d6c:74ced639ac1ecb22d9cbea5192bcfa90
KKD - So, until you get the patent assigned to you, you cannot begin the Anavex Plus trial, correct?
CM - No. All patents are irrevocably assigned or owned by Anavex.
http://seekingalpha.com/article/3354385-anavex-may-actually-cure-alzheimers
Anavex May Actually Cure Alzheimer's
https://au.news.yahoo.com/video/watch/29015798/new-pills-offer-hope-for-alzheimers-sufferers/#page1
"It's like being in the dark and someone switched the light on."
http://www.heraldsun.com.au/news/victorians-first-to-trial-breakthrough-brain-booster-pill/story-fni0fiyv-1227453139615
A PILL to treat Alzheimer’s disease is four times more effective than the current treatment in boosting the brain power of patients.
“We’ve also had patients and their carers reporting improvements in their thinking, increased alertness and improvement in their organisation and independence,” Prof Macfarlane said.
http://thestockradio.com/otcqx-avxl-anavex-life-sciences-corp-ceo-pres-christopher-missling-2050.html
http://www.anavex.com/
Corporate Presentation - Spring 2015
http://www.endevr.com/dementia/New-drug-might-help-prevent-slow-or-reverse-Alzheimer-s
Findings in a recent peer-reviewed scientific journal reveals that our lead drug, ANAVEX 2-73 has the potential to prevent, stop, slow or reverse the disease, in addition to treating its symptoms.
I think we're ready to move up now too -
The last run was from .78 to 1.67.
We have now retraced 50%. Buy Buy Buy
I'm still liking today even though we closed red. The announcement of fully funded 2-73 Parkinson's research is awesome.
We could be in a Phase 2 Parkinson's trial in a year.
Fox's foundation has doled out $450 million to research so far. Great 2-73 pre-clinical results may persuade them to pick up the tab for Phase 2.
Nice job on the DD, WW -
AVXL's last 10-Q was filed on 5-14.
They filed under - Smaller reporting company [X]
I believe that they will be allowed to continue as a smaller reporting company at least until the end of their fiscal year, regardless of their market cap.
The 10-Q is due on 8-14. AVXL could file earlier.
“Accelerated filer” is defined as a company that meets the following conditions:
1. Has at least $75 million, but less than $700 million, in worldwide1 market value of the voting and non-voting common equity held by non-affiliates (“worldwide public float”) as of the last business day of its most recently completed second fiscal quarter;
2. Has been subject to the periodic reporting requirements pursuant to Exchange Act Section 13(a) or 15(d) for at least twelve calendar months;
3. Has previously filed at least one annual report pursuant to Section 13(a) or 15(d) under the Exchange Act; and
4. Is not eligible to file “Small Business” forms.
I agree, but, only if the MMSE numbers are an accurate portrayal of what is actually happening within the AD patients and not some misguided measuring statistic.
Yes, I realize that and thank you for that message -
It's never enjoyable when negativity rules the board.
Ha Ha, all the negative spins this morning in an effort to purchase cheaper shares. Shameful!
We know that 2-73 is working amazingly well in the first batch of patients at 36 days.
What we don't know is how much better 2-73 will work once the dose is optimized and how much the 4x better than donepezil will improve at 3 months and 6 months.
Listen to the patients and care providers. They are experiencing 2-73 results hands on. The board hucksters are trying to play us for suckers!
“This is the first time the investigational drug ANAVEX 2-73 has been administered to Alzheimer’s patients. In addition to the positive EEG/ERP P300 biomarker signal, the feedback we’ve had so far is that patients and care providers have noticed both cognitive and functional improvement, increased alertness, improvement in activities of daily living, greater organization and a requirement for less prompting,” said study’s principal investigator Dr. Stephen Macfarlane, FRANZCP, Associate Professor and Director of Aged Psychiatry at The Alfred Hospital. “Subsequent to the positive initial feedback, we are applying to expand the extension period from 26 weeks to 52 weeks at the request of the participants.”
http://www.anavex.com/?post_type=news&p=1491
I have read a couple articles written by former market makers. These articles explained how market makers(MM) operate. What I came away with is the following -
MM don't want to take on the risk of being too long or short a stock. They try to be neutral and make their money from executions of orders to buy or sell.
When a MM fills a sell order, without having the shares in his inventory, he is temporarily short the stock. This short is reported as short volume (not to be confused with short sales) even though he will have the shares in hand in nano-seconds from the seller. Only the first part of the transaction is reported to Finra as short volume. The almost instant cover is not reported to eliminate double counting of the sell order.
This is why the daily short volume some people like to focus on is meaningless. Only the bi-monthly short sales reported by the exchanges are meaningful.
Short squeezes are not a myth. Buy side institutions can create a short squeeze. Fidelity Investments has a reputation for doing this and is feared by the shorts.
Major drops in share price is not driven by the MM. Short hedge funds create panic selling and drive the price down to take out stops, not MM.
FDA approved device +
In addition to the positive EEG/ERP P300 biomarker signal, the feedback we’ve had so far is that patients and care providers have noticed both cognitive and functional improvement, increased alertness, improvement in activities of daily living, greater organization and a requirement for less prompting,” said study’s principal investigator Dr. Stephen Macfarlane, FRANZCP, Associate Professor and Director of Aged Psychiatry at The Alfred Hospital. “Subsequent to the positive initial feedback, we are applying to expand the extension period from 26 weeks to 52 weeks at the request of the participants.”
I haven't seen those that are trying to discredit 2-73's data even try to BS their way past the above statement.
I know the feeling -
So do traders that have been around for awhile. The big one is very difficult to find and so easy to let go.
All it takes is a keyboard click.
You're right, playing the short term trading game is definitely risky. A number of posters have posted that they sold, hoping to get back in later at a lower cost, and got burnt.
On 7/27 AVXL closed at $0.91. On 7/28 AVXL closed at $0.78. On 7/28 the message board was overwhelmed with predictions that the rally was over and that no news was coming to support the share price. First time posters, as well as at least one regular, were all sharing their expertise and calling for a pull back into the $0.50s.
Since then the share price has moved to a high of $1.67, 114% higher than $0.78, and has settled at $1.30, 67% higher than $0.78.
Is the move down from $1.67 to $1.30 setting up the next rally like we saw from $0.78 to $1.67?
Too good a chance for a big rally from here to cash out, IMO.
Besides, AVXL is looking to be a monster stock going into the end of the year. Which, also adds to the possibility of another huge short term rally.
Very exciting to hear the Kevetrin related efficacy news. I'm really looking forward to results from future Kevetrin trials where -
750 is the dosage
Multiple weekly dosing
Patients are less than stage 4
Kevetrin alone and in combo with other drugs
Another item I'm excited about -
The AVXL weekly chart is a thing of beauty.
You can't ask for much more than that.
The shorts will most likely be pissed and broke before long. They've not been able to manipulate this stock. There are too many people that want to own it.
I've been a shareholder since late April. I held through the data release and I'm still having a hard time fully comprehending the magnitude of Anavex's first data release.
Thank You, good info!
A couple more positive data reports and an up listing will get us there!
You're right, this is a key part of the press release -
Bought 1.59 - UNREAL
The Hammer formation is created when the open, high, and close are roughly the same price. Also, there is a long lower shadow, twice the length as the real body.
http://www.onlinetradingconcepts.com/TechnicalAnalysis/Candlesticks/Hammer.html